The U.S. Food and Drug Administration has granted approval for LEMBAZ™ (adrabetadex), marking the first medicine to address the cholesterol‑trafficking defect that causes Niemann‑Pick disease type C (NPC) and the first to improve survival in infantile‑onset NPC (I‑NPC). The announcement, made in Thousand Oaks, Calif., is significant for local families facing this rare, neurodegenerative disorder because the drug is now available at commercial sites nationwide, with rollout beginning in early December.
According to Business Wire, LEMBAZ is approved for adults and children with NPC who exhibited neurological symptoms before age six. Clinical data from three studies and an Expanded Access Program showed a 55 percent reduction in the risk of mortality compared with matched external controls, a result the FDA deemed sufficient for approval.
“For children and families with infantile‑onset NPC, this long‑awaited approval brings a new kind of hope for the future,” said Heather Moran‑Teal, Executive Director of the National Niemann‑Pick Disease Foundation. “These encouraging survival findings carry profound meaning and hope for more time together.” Elizabeth M. Berry‑Kravis, M.D., Ph.D., lead investigator for the Expanded Access Program, added that early diagnosis and prompt treatment are critical because neurological loss cannot be regained.
Beren Therapeutics, the public benefit corporation behind LEMBAZ, highlighted its commitment to supporting families beyond the drug itself. The company has launched two initiatives: the LEMBAZ Family Support program and the Caregiver Ambassador Program. Both are designed to provide a single point of contact, assist with insurance and logistics, and offer full out‑of‑pocket financial assistance for eligible patients.
“Proximity to an administration site should never stand between a family and treatment,” said Bennett Smith, Senior Vice President, Commercial at Beren Therapeutics. “With LEMBAZ available at commercial sites nationwide and Family Access Managers supporting caregivers to find a site, patients will have an opportunity to start treatment quickly.” Jason Camm, CEO of Beren Therapeutics, emphasized that the approval reflects nearly two decades of collaboration among patients, families, researchers, and the FDA.
Families in Thousand Oaks can expect to access LEMBAZ through local oncology or specialty centers once the early‑December rollout begins. Beren has assigned a dedicated Family Access Manager to help identify the nearest treatment site and coordinate insurance coverage, travel logistics, and any needed financial assistance.
What’s next: Residents seeking LEMBAZ for an eligible family member should contact Beren Therapeutics’ Family Access team as soon as the drug becomes available in early December. The company’s support programs remain open to guide families through diagnosis, site selection, and treatment initiation.
Sources: berentx.com, biospace.com